REGENERON PHARMACEUTICALS, INC. Stock-Based Compensation
REGENERON PHARMACEUTICALS, INC. (REGN) reported Stock-Based Compensation of $500.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $243.00M, a 3.46% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $257.40M, a 0.66% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $249.30M, a 18.10% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $237.00M, a 5.29% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $993.70M, a 1.11% increase from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $982.80M, a 11.05% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $885.00M, a 22.07% increase from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $725.00M, a 20.49% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $243.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $500.40M 10-Q · filed 2026-07-30 | $749.70M derived: sum of 3 quarters · filed 2026-07-30 | $986.70M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $257.40M 10-Q · filed 2026-04-29 | $506.70M derived: sum of 2 quarters · filed 2026-04-29 | $743.70M derived: sum of 3 quarters · filed 2026-04-29 | $995.40M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $249.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $486.30M derived: sum of 2 quarters · filed 2026-02-04 | $738.00M derived: sum of 3 quarters · filed 2026-07-30 | $993.70M 10-K · filed 2026-02-04 | ||||
| 2025-09-30 | $237.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $488.70M derived: sum of 2 quarters · filed 2026-07-30 | $744.40M 10-Q · filed 2025-10-28 | $1.05B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $251.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $507.40M 10-Q · filed 2026-07-30 | $811.80M derived: sum of 3 quarters · filed 2026-07-30 | $1.04B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $255.70M 10-Q · filed 2026-04-29 | $560.10M derived: sum of 2 quarters · filed 2026-04-29 | $785.20M derived: sum of 3 quarters · filed 2026-04-29 | $1.01B derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | $304.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $529.50M derived: sum of 2 quarters · filed 2026-02-04 | $752.70M derived: sum of 3 quarters · filed 2026-02-04 | $982.80M 10-K · filed 2026-02-04 | ||||
| 2024-09-30 | $225.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $448.30M derived: sum of 2 quarters · filed 2025-10-28 | $678.40M 10-Q · filed 2025-10-28 | $918.80M derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-06-30 | $223.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $453.30M 10-Q · filed 2025-08-01 | $693.70M derived: sum of 3 quarters · filed 2026-02-04 | $897.60M derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-03-31 | $230.10M 10-Q · filed 2025-04-29 | $470.50M derived: sum of 2 quarters · filed 2026-02-04 | $674.40M derived: sum of 3 quarters · filed 2026-02-04 | $876.40M derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2023-12-31 | $240.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $444.30M derived: sum of 2 quarters · filed 2026-02-04 | $646.30M derived: sum of 3 quarters · filed 2026-02-04 | $885.00M 10-K · filed 2026-02-04 | ||||
| 2023-09-30 | $203.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $405.90M derived: sum of 2 quarters · filed 2024-10-31 | $644.60M 10-Q · filed 2024-10-31 | $876.60M derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-06-30 | $202.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $440.70M 10-Q · filed 2024-08-01 | $672.70M derived: sum of 3 quarters · filed 2025-02-05 | $839.00M derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-03-31 | $238.70M 10-Q · filed 2024-05-02 | $470.70M derived: sum of 2 quarters · filed 2025-02-05 | $637.00M derived: sum of 3 quarters · filed 2025-02-05 | $796.80M derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2022-12-31 | $232.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-05 | $398.30M derived: sum of 2 quarters · filed 2025-02-05 | $558.10M derived: sum of 3 quarters · filed 2025-02-05 | $725.00M 10-K · filed 2025-02-05 | ||||
| 2022-09-30 | $166.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $326.10M derived: sum of 2 quarters · filed 2023-11-02 | $493.00M 10-Q · filed 2023-11-02 | $681.40M derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-06-30 | $159.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $326.70M 10-Q · filed 2023-08-03 | $515.10M derived: sum of 3 quarters · filed 2024-02-05 | $652.00M derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-03-31 | $166.90M 10-Q · filed 2023-05-04 | $355.30M derived: sum of 2 quarters · filed 2024-02-05 | $492.20M derived: sum of 3 quarters · filed 2024-02-05 | $637.70M derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2021-12-31 | $188.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | $325.30M derived: sum of 2 quarters · filed 2024-02-05 | $470.80M derived: sum of 3 quarters · filed 2024-02-05 | $601.70M 10-K · filed 2024-02-05 | ||||
| 2021-09-30 | $136.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $282.40M derived: sum of 2 quarters · filed 2022-11-03 | $413.30M 10-Q · filed 2022-11-03 | $534.80M derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-06-30 | $145.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $276.40M 10-Q · filed 2022-08-03 | $397.90M derived: sum of 3 quarters · filed 2023-02-06 | $499.10M derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-03-31 | $130.90M 10-Q · filed 2022-05-04 | $252.40M derived: sum of 2 quarters · filed 2023-02-06 | $353.60M derived: sum of 3 quarters · filed 2023-02-06 | $457.10M derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2020-12-31 | $121.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | $222.70M derived: sum of 2 quarters · filed 2023-02-06 | $326.20M derived: sum of 3 quarters · filed 2023-02-06 | $432.00M 10-K · filed 2023-02-06 | ||||
| 2020-09-30 | $101.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $204.70M derived: sum of 2 quarters · filed 2021-11-04 | $310.50M 10-Q · filed 2021-11-04 | $444.00M derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-06-30 | $103.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $209.30M 10-Q · filed 2021-08-05 | $342.80M derived: sum of 3 quarters · filed 2022-02-07 | $459.90M derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-03-31 | $105.80M 10-Q · filed 2021-05-06 | $239.30M derived: sum of 2 quarters · filed 2022-02-07 | $356.40M derived: sum of 3 quarters · filed 2022-02-07 | $462.20M derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2019-12-31 | $133.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-07 | $250.60M derived: sum of 2 quarters · filed 2022-02-07 | $356.40M derived: sum of 3 quarters · filed 2022-02-07 | $464.30M 10-K · filed 2022-02-07 | ||||
| 2019-09-30 | $117.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $222.90M derived: sum of 2 quarters · filed 2020-11-05 | $330.80M 10-Q · filed 2020-11-05 | $457.50M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-06-30 | $105.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $213.70M 10-Q · filed 2020-08-05 | $340.40M derived: sum of 3 quarters · filed 2021-02-08 | $451.90M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-03-31 | $107.90M 10-Q · filed 2020-05-05 | $234.60M derived: sum of 2 quarters · filed 2021-02-08 | $346.10M derived: sum of 3 quarters · filed 2021-02-08 | $452.90M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2018-12-31 | $126.70M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-08 | $238.20M derived: sum of 2 quarters · filed 2021-02-08 | $345.00M derived: sum of 3 quarters · filed 2021-02-08 | $427.40M 10-K · filed 2021-02-08 | ||||
| 2018-09-30 | $111.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $218.30M derived: sum of 2 quarters · filed 2019-11-05 | $300.70M 10-Q · filed 2019-11-05 | $300.65M 10-Q · filed 2018-11-06 | $427.86M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-06-30 | $106.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $189.20M 10-Q · filed 2019-08-06 | $189.22M 10-Q · filed 2018-08-02 | $316.36M derived: sum of 3 quarters · filed 2020-02-07 | $441.45M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-03-31 | $82.40M 10-Q · filed 2019-05-07 | $82.42M 10-Q · filed 2018-05-03 | $209.56M derived: sum of 2 quarters · filed 2020-02-07 | $334.65M derived: sum of 3 quarters · filed 2020-02-07 | $455.91M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2017-12-31 | $127.16M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $252.25M derived: sum of 2 quarters · filed 2020-02-07 | $373.51M derived: sum of 3 quarters · filed 2020-02-07 | $507.30M 10-K · filed 2020-02-07 | $507.28M 10-K · filed 2018-02-08 | |||
| 2017-09-30 | $125.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $246.35M derived: sum of 2 quarters · filed 2018-11-06 | $380.14M 10-Q · filed 2018-11-06 | $534.72M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-06-30 | $121.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $255.05M 10-Q · filed 2018-08-02 | $409.63M derived: sum of 3 quarters · filed 2019-02-07 | $541.01M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-03-31 | $133.79M 10-Q · filed 2018-05-03 | $288.37M derived: sum of 2 quarters · filed 2019-02-07 | $419.75M derived: sum of 3 quarters · filed 2019-02-07 | $551.44M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2016-12-31 | $154.58M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $285.96M derived: sum of 2 quarters · filed 2019-02-07 | $417.65M derived: sum of 3 quarters · filed 2019-02-07 | $559.90M 10-K · filed 2019-02-07 | $559.88M 10-K · filed 2017-02-09 | |||
| 2016-09-30 | $131.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $263.07M derived: sum of 2 quarters · filed 2017-11-08 | $405.32M 10-Q · filed 2017-11-08 | $563.71M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-06-30 | $131.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $273.94M 10-Q · filed 2017-08-03 | $432.33M derived: sum of 3 quarters · filed 2018-02-08 | $534.93M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-03-31 | $142.25M 10-Q · filed 2017-05-04 | $300.64M derived: sum of 2 quarters · filed 2018-02-08 | $403.24M derived: sum of 3 quarters · filed 2018-02-08 | $497.50M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2015-12-31 | $158.39M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $260.99M derived: sum of 2 quarters · filed 2018-02-08 | $355.25M derived: sum of 3 quarters · filed 2018-02-08 | $459.05M 10-K · filed 2018-02-08 | ||||
| 2015-09-30 | $102.60M 10-Q · filed 2015-11-04 | $196.86M derived: sum of 2 quarters · filed 2015-11-04 | $300.66M 10-Q · filed 2016-11-04 | $413.63M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-06-30 | $94.26M 10-Q · filed 2015-08-04 | $198.02M 10-Q · filed 2016-08-04 | $311.03M derived: sum of 3 quarters · filed 2017-02-09 | $379.13M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-03-31 | $103.76M 10-Q · filed 2016-05-05 | $216.78M derived: sum of 2 quarters · filed 2017-02-09 | $284.88M derived: sum of 3 quarters · filed 2017-02-09 | $349.70M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2014-12-31 | $113.02M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $181.12M derived: sum of 2 quarters · filed 2017-02-09 | $245.95M derived: sum of 3 quarters · filed 2017-02-09 | $321.75M 10-K · filed 2017-02-09 | $307.24M 10-K · filed 2015-02-12 | |||
| 2014-09-30 | $68.10M 10-Q · filed 2015-11-04 | $132.93M derived: sum of 2 quarters · filed 2015-11-04 | $208.73M 10-Q · filed 2015-11-04 | $225.78M 10-Q · filed 2014-11-04 | $280.87M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2014-06-30 | $64.83M 10-Q · filed 2015-08-04 | $140.61M 10-Q · filed 2015-08-04 | $151.92M 10-Q · filed 2014-08-05 | $212.77M derived: sum of 3 quarters · filed 2016-02-11 | $258.52M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2014-03-31 | $75.78M 10-Q · filed 2015-05-07 | $81.41M 10-Q · filed 2014-05-08 | $147.94M derived: sum of 2 quarters · filed 2016-02-11 | $193.69M derived: sum of 3 quarters · filed 2016-02-11 | $238.13M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2013-12-31 | $72.16M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $117.90M derived: sum of 2 quarters · filed 2016-02-11 | $162.35M derived: sum of 3 quarters · filed 2016-02-11 | $215.38M 10-K · filed 2016-02-11 | $198.40M 10-K · filed 2014-02-13 | |||
| 2013-09-30 | $45.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $90.19M derived: sum of 2 quarters · filed 2014-11-04 | $143.22M 10-Q · filed 2014-11-04 | $173.99M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-06-30 | $44.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $97.47M 10-Q · filed 2014-08-05 | $128.25M derived: sum of 3 quarters · filed 2015-02-12 | $148.78M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-03-31 | $53.03M 10-Q · filed 2014-05-08 | $83.80M derived: sum of 2 quarters · filed 2015-02-12 | $104.34M derived: sum of 3 quarters · filed 2015-02-12 | $123.94M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2012-12-31 | $30.77M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $51.31M derived: sum of 2 quarters · filed 2015-02-12 | $70.91M derived: sum of 3 quarters · filed 2015-02-12 | $94.16M 10-K · filed 2015-02-12 | ||||
| 2012-09-30 | $20.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $40.14M derived: sum of 2 quarters · filed 2013-11-05 | $63.38M 10-Q · filed 2013-11-05 | $78.92M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-06-30 | $19.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $42.85M 10-Q · filed 2013-08-06 | $58.38M derived: sum of 3 quarters · filed 2014-02-13 | $71.75M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-03-31 | $23.24M 10-Q · filed 2013-05-03 | $38.78M derived: sum of 2 quarters · filed 2014-02-13 | $52.14M derived: sum of 3 quarters · filed 2014-02-13 | $64.54M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2011-12-31 | $15.53M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13 | $28.90M derived: sum of 2 quarters · filed 2014-02-13 | $41.29M derived: sum of 3 quarters · filed 2014-02-13 | $56.09M 10-K · filed 2014-02-13 | ||||
| 2011-09-30 | $13.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $25.76M derived: sum of 2 quarters · filed 2012-10-24 | $40.56M 10-Q · filed 2012-10-24 | $54.13M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-06-30 | $12.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | $27.20M 10-Q · filed 2012-07-25 | $40.76M derived: sum of 3 quarters · filed 2013-02-15 | $49.55M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-03-31 | $14.80M 10-Q · filed 2012-04-26 | $28.37M derived: sum of 2 quarters · filed 2013-02-15 | $37.16M derived: sum of 3 quarters · filed 2013-02-15 | $45.86M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2010-12-31 | $13.57M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $22.36M derived: sum of 2 quarters · filed 2013-02-15 | $31.06M derived: sum of 3 quarters · filed 2013-02-15 | $39.90M 10-K · filed 2013-02-15 | ||||
| 2010-09-30 | $8.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $17.50M derived: sum of 2 quarters · filed 2011-10-27 | $26.33M 10-Q · filed 2011-10-27 | |||||
| 2010-06-30 | $8.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $17.54M 10-Q · filed 2011-07-28 | ||||||
| 2010-03-31 | $8.83M 10-Q · filed 2011-05-03 | |||||||
| 2009-12-31 | $31.26M 10-K · filed 2012-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |